← Eichor
Study identifier: NCT05500807 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Emicizumab for Severe Von Willebrand Disease (VWD) and VWD/Hemophilia A

Condition: Von Willebrand Disease, Type 3 · Concomitant VWD and Hemophilia  ·  Sponsor: Bleeding and Clotting Disorders Institute Peoria, Illinois

PhasePhase 1
Planned participants40
Who can joinAll sexes, 0 Years to 90 Years
Healthy volunteersNo

About this study

Von Willebrand Disease (VWD) is the most common inherited bleeding disorder affecting up to 0.1% of the population, is usually characterized by mucocutaneous bleeding, HMB, surgical bleeding or other hemostatic challenges. Severe bleeding events require VWF concentrates administered solely through intravenous access. Emicizumab (Hemlibra) is a monoclonal bispecific antibody developed to bind activated FIX and FX and mimic FVIII cofactor functionality. Hemlibra is administered via subcutaneous injection rather than intravenous infusion. The hypothesis of this study is that Emicizumab is safe and efficacious for prophylaxis in severe VWD and concomitant VWD/hemophilia patients.

This description comes directly from the study's public registry record.

Talk to the study team

Megan L Woodbury, PhD  ·  309-692-5337  ·  meganw@ilbcdi.org

Dayna Lenski, BS  ·  309-692-5337  ·  dayna@ilbcdi.org

Always discuss trial participation with your own doctor first.

Locations (12)

The Center for Comprehensive Care and Diagnosis of Inherited Blood Disorders (CIBD)Orange, California, United StatesRecruiting
Stanford University: Stanford Children's HealthRedwood City, California, United StatesRecruiting
University of Miami - Miller School of MedicineCoral Gables, Florida, United StatesRecruiting
St. Joseph's Children's Hospital - Center for Bleeding and Clotting DisordersTampa, Florida, United StatesRecruiting
Bleeding and Clotting Disorders Institute (BCDI)Peoria, Illinois, United StatesRecruiting
Innovative Hematology, Inc. (IHI)Indianapolis, Indiana, United StatesRecruiting
University of Michigan Medical SchoolAnn Arbor, Michigan, United StatesRecruiting
Central Michigan University: Children's Hospital of MichiganMount Pleasant, Michigan, United StatesRecruiting
Children's Mercy HospitalKansas City, Missouri, United StatesRecruiting
Penn State College of MedicineHershey, Pennsylvania, United StatesRecruiting
Washington Center for Bleeding DisordersSeattle, Washington, United StatesRecruiting
UW Health Comprehensive Program for Bleeding DisordersMadison, Wisconsin, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05500807